SeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy

Reuters

2025/08/14

SeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy

SeaStar Medical Holding Corporation has announced significant progress in its clinical trials and market expansion. The company has reached the 50% patient enrollment milestone in its NEUTRALIZE-AKI pivotal clinical trial, with 125 of the anticipated 200 patients now enrolled. Interim analysis results from the trial's independent Data Safety Monitoring Review Board are expected in the third quarter of 2025. Additionally, SeaStar Medical has expanded its QUELIMMUNE customer base by securing three top-rated U.S.-based children's hospitals. Positive survival results have been reported for the first 20 pediatric patients treated with QUELIMMUNE in a commercial setting, as part of the SAVE Surveillance Registry. The company plans to file a Pre-Marketing Approval application for its Selective Cytopheretic Device therapy in 2026, contingent upon successful trial outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001831868-25-000006), on August 13, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559981321"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559981321\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559981321?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559981321","market":"nz","top_or_hot":-1,"title":"SeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICU\">SeaStar Medical Holding Corporation</a> has announced significant progress in its clinical trials and market expansion. The company has reached the 50% patient enrollment milestone in its NEUTRALIZE-AKI pivotal clinical trial, with 125 of the anticipated 200 patients now enrolled. Interim analysis results from the trial's independent Data Safety Monitoring Review Board are expected in the third quarter of 2025. Additionally, SeaStar Medical has expanded its QUELIMMUNE customer base by securing three top-rated U.S.-based children's hospitals. Positive survival results have been reported for the first 20 pediatric patients treated with QUELIMMUNE in a commercial setting, as part of the SAVE Surveillance Registry. The company plans to file a Pre-Marketing Approval application for its Selective Cytopheretic Device therapy in 2026, contingent upon successful trial outcomes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001831868-25-000006), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-14 04:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICU\">SeaStar Medical Holding Corporation</a> has announced significant progress in its clinical trials and market expansion. The company has reached the 50% patient enrollment milestone in its NEUTRALIZE-AKI pivotal clinical trial, with 125 of the anticipated 200 patients now enrolled. Interim analysis results from the trial's independent Data Safety Monitoring Review Board are expected in the third quarter of 2025. Additionally, SeaStar Medical has expanded its QUELIMMUNE customer base by securing three top-rated U.S.-based children's hospitals. Positive survival results have been reported for the first 20 pediatric patients treated with QUELIMMUNE in a commercial setting, as part of the SAVE Surveillance Registry. The company plans to file a Pre-Marketing Approval application for its Selective Cytopheretic Device therapy in 2026, contingent upon successful trial outcomes.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001831868-25-000006), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICU","symbol_name":"SeaStar Medical Holding Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL6V6DKb:1","article_id":"2559981321","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559981321","pubTimestamp":1755116376,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SeaStar Medical Holding Corporation has announced significant progress in its clinical trials and market expansion. The company has reached the 50% patient enrollment milestone in its NEUTRALIZE-AKI pivotal clinical trial, with 125 of the anticipated 200 patients now enrolled. Interim analysis results from the trial's independent Data Safety Monitoring Review Board are expected in the third quarter of 2025. Additionally, SeaStar Medical has expanded its QUELIMMUNE customer base by securing three top-rated U.S.-based children's hospitals. Positive survival results have been reported for the first 20 pediatric patients treated with QUELIMMUNE in a commercial setting, as part of the SAVE Surveillance Registry. The company plans to file a Pre-Marketing Approval application for its Selective Cytopheretic Device therapy in 2026, contingent upon successful trial outcomes.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ICU":"SeaStar Medical Holding Corporation"},"translate_title":"SeaStar Medical推进NEUTRALIZE-AKI试验，入组率超过60%，计划2026年向PMA提交SCD治疗申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICU":0.9},"content_text":"SeaStar Medical Advances NEUTRALIZE-AKI Trial with Over 60% Enrollment, Plans 2026 PMA Filing for SCD Therapy\n    \n\nSeaStar Medical Holding Corporation has announced significant progress in its clinical trials and market expansion. The company has reached the 50% patient enrollment milestone in its NEUTRALIZE-AKI pivotal clinical trial, with 125 of the anticipated 200 patients now enrolled. Interim analysis results from the trial's independent Data Safety Monitoring Review Board are expected in the third quarter of 2025. Additionally, SeaStar Medical has expanded its QUELIMMUNE customer base by securing three top-rated U.S.-based children's hospitals. Positive survival results have been reported for the first 20 pediatric patients treated with QUELIMMUNE in a commercial setting, as part of the SAVE Surveillance Registry. The company plans to file a Pre-Marketing Approval application for its Selective Cytopheretic Device therapy in 2026, contingent upon successful trial outcomes.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001831868-25-000006), on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}